Navigation Links
Aspirin as Good as Plavix for Poor Leg Circulation: Study
Date:2/21/2012

By Steven Reinberg
HealthDay Reporter

TUESDAY, Feb. 21 (HealthDay News) -- Aspirin works as well as Plavix in patients with blocked leg arteries, a new European study finds.

People with the condition, called peripheral artery disease, often suffer from intermittent claudication, which is pain while walking because of decreased blood supply to the legs. Animal experiments had suggested that aspirin might block the growth of blood vessels that bypass blockages and help get more blood to leg tissue, the Swiss and German researchers said.

"Once again, we have shown that what happens in animals doesn't translate to humans," said Dr. Juan Zambrano, an assistant professor of cardiovascular medicine, coronary/endovascular and stem cell therapies at the University of Miami Miller School of Medicine.

Patients suffering from peripheral artery disease are also at increased risk of heart attack and stroke from blood clots traveling from the legs to the heart or brain, which is why these patients are given blood thinners such as Plavix (clopidogrel) or aspirin, explained Zambrano.

"Either aspirin or Plavix is acceptable as a good preventive measure to avoid heart attack or stroke in these patients," he said. "A lot of people favor aspirin because it's cheaper."

However, the most interesting part of this study to Zambrano was the role of exercise in improving walking distance and time.

"Something as simple as exercise can help improve claudication," he said. "Exercise is key and it doesn't matter how you treat the underlying condition, exercise is always going to help."

The report was published online Feb. 21 in the journal Cardiovascular and Cerebrovascular Disease.

For the study, a team led by Dr. Kurt Jaeger from University Hospital Basel in Switzerland, looked at the effectiveness of aspirin and Plavix in helping peripheral artery disease patients improve pain-free walking distance, which is a vital part of rehabilitation.

The researchers randomly assigned 229 patients to receive low-dose aspirin or Plavix, to see how they did during one hour walks.

Jaeger's group found that, after 12 weeks, people taking aspirin improved pain-free walking distance almost 40 percent and could walk 35 percent longer before pain made it too hard to continue.

For patients taking Plavix, there was a 33 percent improvement in walking distance and an almost 35 improvement in pain-free walking time, the researchers noted.

Walking is an important part of rehabilitation for peripheral artery disease patients. Walking can help increase blood flow to the legs and promote the growth of tiny blood vessels that help supply the leg with blood and oxygen.

It had been thought that aspirin wouldn't work because its anti-inflammatory properties could block the development of these tiny blood vessels that grow to get blood around the blockage.

"It seems that the anti-inflammatory properties of low-dose aspirin and its inhibiting effects on [the growth of new blood vessels] are not of clinical relevance for rehabilitation programs in intermittent claudication," the researchers concluded.

More information

For more on peripheral artery disease, visit the American Heart Association.

SOURCES: Juan P. Zambrano, M.D., assistant professor, cardiovascular medicine, coronary/endovascular and stem cell therapies, University of Miami Miller School of Medicine; Feb. 21, 2012, Cardiovascular and Cerebrovascular Disease


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
2. Low-Dose Aspirin to Prevent First Heart Attack or Stroke? Not So Fast
3. Could Daily Aspirin Harm Seniors Eyes?
4. Low-Dose Aspirin After Lung Clot Could Prevent Recurrence
5. Preoperative aspirin therapy can benefit cardiac surgery patients
6. Daily Aspirin May Help Prevent Colon Cancer for Those at High Risk
7. Scientists prove regular aspirin intake halves cancer risk
8. Even low-dose aspirin may increase risk of GI bleeding
9. No Proof That Aspirin Aids Conception, Review Shows
10. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
11. Higher daily dose of aspirin could play key role in preventing heart attacks for those with diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Aspirin as Good as Plavix for Poor Leg Circulation: Study 
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages ... Association™ (ALCA) to conduct a survey that takes a closer look at cases of ... the prevalence and causes of TBI among the aging population, and identifies the challenges ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors (UBA), the ... addition to its growing list of Partner Firms. S.S. Nesbitt is headquartered ... to Huntsville and in between. , Harnessing the experience and insights of the ...
(Date:2/10/2016)... , ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: ... report results for the fourth quarter and full year ended December 31, 2015 on ... conference call and webcast for the investment community following the release at 4:30 PM ...
(Date:2/10/2016)... ... ... AHRA: The Association for Medical Imaging Management announced today ... as keynote speaker at the organization’s 2016 Spring Conference. Fox’s topic, Lead with ... with their own organizational staff and leadership. , “I am so excited ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 --> --> ... Japan .  --> Japan .  --> A ... With submission, Shire continues to strengthen ... With submission, Shire continues to strengthen its presence ... submission, Shire continues to strengthen its presence ...
(Date:2/10/2016)... SEATTLE , Feb. 10, 2016  Resolve ... potentially transformative new approaches to the treatment of ... completion of a multiple ascending dose study in ... lead compound RSLV-132. --> ... double-blind, placebo-controlled multiple ascending dose study of RSLV-132 ...
(Date:2/10/2016)... YORK , Feb. 10, 2016 Immune ... biopharmaceutical company, announced today that it has filed a ... Leukemia and other cancers. --> ... treating cancer by administration of Ceplene (histamine dihydrochloride) in ... provides methods of predicting the efficacy of Ceplene and ...
Breaking Medicine Technology: